Across TCGA pan-cancer cohorts, LIN54 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LIN54 data layer compared with 22 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LIN54 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LIN54 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.
CCRCC, PDAC, and GBM are the cancer types where LIN54 mass-spec protein most reproducibly stratifies survival.